Adoptive T Cell Therapy Targeting CD1 and MR1.

Abstract

Adoptive T cell immunotherapy has demonstrated clinically relevant efficacy in treating malignant and infectious diseases. However, much of these therapies have been focused on enhancing, or generating de novo, effector functions of conventional T cells recognizing HLA molecules. Given the heterogeneity of HLA alleles, mismatched patients are ineligible for current HLA-restricted adoptive T cell therapies. CD1 and MR1 are class I-like monomorphic molecules and their restricted T cells possess unique T cell receptor specificity against entirely different classes of antigens. CD1 and MR1 molecules present lipid and vitamin B metabolite antigens, respectively, and offer a new front of targets for T cell therapies. This review will cover the recent progress in the basic research of CD1, MR1, and their restricted T cells that possess translational potential.

• Authors: Tingxi Guo, Kenji Chamoto, Naoto Hirano
• Journal: Frontiers in immunology (Front Immunol) Vol. 6 Pg. 247 ( 2015) ISSN: 1664-3224 [Print] Switzerland
• PMID: 26052329 (Publication Type: Journal Article, Review)